{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:03:55Z","timestamp":1793707435267,"version":"4.6.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Concept Medical Inc. Tampa, USA"},{"DOI":"10.13039\/100012957","name":"Friedrich-Schiller-Universit\u00e4t Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CVIR Endovasc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The randomised SIRONA trial showed that sirolimus-coated balloon (SCB) angioplasty was non-inferior to paclitaxel-coated balloon angioplasty (PCB) regarding femoropopliteal primary patency. There was no difference in clinically driven target lesion revascularisation (cdTLR) rates between the treatment groups. This post-hoc analysis aimed to assess whether the overall results were consistent across different subgroups and selected post-baseline factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary patency at 12\u00a0months was assessed using duplex ultrasound and adjudicated by a core laboratory for 203 and 199 participants in the SCB and PCB groups, respectively (available-case intention-to-treat analysis). Data on 12-month cdTLR were available for 238 and 244 participants in the SCB and PCB groups, respectively. Odds ratios (ORs) for primary patency and hazard ratios (HRs) for cdTLR after SCB compared to PCB in non-pre-specified subgroups were assessed using generalised linear mixed models to control for centre effects, and Cox proportional hazards models, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Primary patency and cdTLR were generally consistent across the analysed subgroups. Two nominal interaction signals were observed. For cdTLR, a nominal interaction with age was identified (interaction\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047); among participants older than 70\u00a0years, the estimated hazard ratio favoured SCB (HR 0.52, 95% CI 0.16\u20131.71). For primary patency, treatment effects differed according to residual diameter stenosis (interaction\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.022); the estimated treatment effect favoured SCB in participants with residual diameter stenosis\u2009&gt;\u200930% (OR 1.67, 95% CI 0.76\u20133.65). No other interactions between treatment and subgroup or post-baseline factors were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The effectiveness of SCB compared to PCB was similar and mainly consistent among subgroups. The evaluation should be considered exploratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, NCT04475783. Registered 17 July 2020,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT4475783\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT4475783<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42155-026-00743-2","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:42:16Z","timestamp":1786416136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Subgroup variations in effectiveness of femoropopliteal sirolimus versus paclitaxel-coated balloon angioplasty: post hoc results of the randomised SIRONA trial"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-3938","authenticated-orcid":false,"given":"Ulf","family":"Teichgr\u00e4ber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Ingwersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Platzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Kunstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Thieme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Krankenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Malyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"M\u00fcller-H\u00fclsbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"de Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Austermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Erbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulf","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Wa\u00dfmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Maiwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Aschenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wissgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Andrassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Beschorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dierk","family":"Scheinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eclinm.2019.09.004","volume":"16","author":"C Klumb","year":"2019","unstructured":"Klumb C, Lehmann T, Aschenbach R, Eckardt N, Teichgr\u00e4ber U. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42\u201350.","journal-title":"EClinicalMedicine"},{"issue":"36","key":"743_CR2","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700.","journal-title":"Eur Heart J"},{"key":"743_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.12.017","author":"U Teichgr\u00e4ber","year":"2026","unstructured":"Teichgr\u00e4ber U, Ingwersen M, Lehmann T, et al. Comparison of sirolimus- vs paclitaxel-coated balloon angioplasty for femoropopliteal artery disease: the SIRONA randomized noninferiority trial. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.12.017.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"743_CR4","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/15266028211064816","volume":"29","author":"E Choke","year":"2022","unstructured":"Choke E, Tang TY, Peh E, et al. MagicTouch PTA sirolimus coated balloon for femoropopliteal and below the knee disease: results from XTOSI pilot study up to 12 months. J Endovasc Ther. 2022;29(5):780\u20139.","journal-title":"J Endovasc Ther"},{"issue":"1177\/1526602823","key":"743_CR5","first-page":"152660282312176","volume":"10","author":"M Franzese","year":"2023","unstructured":"Franzese M, Pucciarelli A, Spione F, et al. Sirolimus-coated balloon in femoropopliteal steno-occlusive disease: efficacy, safety, and 1-year outcomes. An all-comers registry J Endovasc Ther. 2023;10(1177\/15266028231217657):15266028231217656.","journal-title":"An all-comers registry J Endovasc Ther"},{"issue":"13","key":"743_CR6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jcin.2024.03.029","volume":"17","author":"O Iida","year":"2024","unstructured":"Iida O, Soga Y, Saito S, et al. A novel sirolimus-coated balloon for the treatment of femoropopliteal lesions: the SELUTION SFA Japan trial. JACC Cardiovasc Interv. 2024;17(13):1547\u201356.","journal-title":"JACC Cardiovasc Interv"},{"issue":"13","key":"743_CR7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jcin.2024.04.042","volume":"17","author":"R Sedhom","year":"2024","unstructured":"Sedhom R, Hamed M, Elbadawi A, et al. Outcomes with limus- vs paclitaxel-coated balloons for percutaneous coronary intervention: meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2024;17(13):1533\u201343.","journal-title":"JACC Cardiovasc Interv"},{"issue":"25","key":"743_CR8","doi-asserted-by":"publisher","first-page":"9463","DOI":"10.1073\/pnas.0400918101","volume":"101","author":"AD Levin","year":"2004","unstructured":"Levin AD, Vukmirovic N, Hwang CW, Edelman ER. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A. 2004;101(25):9463\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"743_CR9","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jacc.2005.09.047","volume":"47","author":"R Wessely","year":"2006","unstructured":"Wessely R, Sch\u00f6mig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47(4):708\u201314.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"743_CR10","first-page":"880","volume":"6","author":"Y Chen","year":"2021","unstructured":"Chen Y, Zeng Y, Zhu X, et al. Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: the basis of better selection of atherosclerosis treatment. Bioact Mater. 2021;6(3):880\u20139.","journal-title":"Bioact Mater"},{"key":"743_CR11","doi-asserted-by":"crossref","unstructured":"Wessely R, Blaich B, Belaiba RS et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97(6):1003\u201312.","DOI":"10.1160\/TH06-10-0586"},{"issue":"1","key":"743_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05631-9","volume":"22","author":"U Teichgr\u00e4ber","year":"2021","unstructured":"Teichgr\u00e4ber U, Ingwersen M, Platzer S, et al. Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial. Trials. 2021;22(1):665.","journal-title":"Trials"},{"issue":"6","key":"743_CR13","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jvs.2004.08.034","volume":"40","author":"RI Vazquez-Padron","year":"2004","unstructured":"Vazquez-Padron RI, Lasko D, Li S, et al. Aging exacerbates neointimal formation, and increases proliferation and reduces susceptibility to apoptosis of vascular smooth muscle cells in mice. J Vasc Surg. 2004;40(6):1199\u2013207.","journal-title":"J Vasc Surg"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ijcard.2020.07.028","volume":"321","author":"T Yamamoto","year":"2020","unstructured":"Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y. Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. Int J Cardiol. 2020;321:30\u20137.","journal-title":"Int J Cardiol"},{"issue":"9","key":"743_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.4244\/EIJ-D-23-00849","volume":"20","author":"M Yamamoto","year":"2024","unstructured":"Yamamoto M, Hara H, Kubota S, Hiroi Y. Predictors of late lumen enlargement after drug-coated balloon angioplasty for de novo coronary lesions. EuroIntervention. 2024;20(9):602\u201312.","journal-title":"EuroIntervention"},{"issue":"8","key":"743_CR16","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1161\/01.RES.86.8.879","volume":"86","author":"CJ Creel","year":"2000","unstructured":"Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86(8):879\u201384.","journal-title":"Circ Res"},{"issue":"11","key":"743_CR17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.jacc.2020.08.007","volume":"76","author":"S Kaul","year":"2020","unstructured":"Kaul S. On the credibility of subgroup analyses in the COMPLETE trial. J Am Coll Cardiol. 2020;76(11):1287\u201390.","journal-title":"J Am Coll Cardiol"}],"container-title":["CVIR Endovascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42155-026-00743-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42155-026-00743-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:42:18Z","timestamp":1786416138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42155-026-00743-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1186\/s42155-026-00743-2","relation":{},"ISSN":["2520-8934"],"issn-type":[{"value":"2520-8934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.\u00a0This study has obtained IRB approval from the Ethics Committee of the Friedrich-Schiller-University Jena, Germany (reference number 2020\u20132012-MPG_ff) and by the local ethics committees of each participating site.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, consent for publication is not required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UT, MI, IK, and RA reported research grants and free supply of the investigational device from Concept Medical to their institution. UT has received speaker honoraria and DS consulting fees from Concept Medical. SP reported funding from Concept Medical for the SIRONA project management. DS reported consulting fees from Concept Medical. SS, AS, TW, TZ, MT, HK, MW, MB, NM, SM-H, LP, OS, MA, GT, CE, WI, RW, LM, CW, MA, FW, and DS reported investigator\u2019s fees to their institution from the Jena University Hospital and free supply of the investigational device from Concept Medical. UB reported fees for core laboratory diagnostics from the Jena University Hospital to his institution. MP reported participation on the CEC of the SIRONA trial. KK reported participation on the DSMB of the SIRONA trial. TL declares no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}